Charbonnier, Aude

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 416

Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients

Nicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 111

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, F.-X., Pfirrmann, M., Dulucq, S., Hochhaus, A., Panayiotidis, P., Almeida, A., Mayer, J., Hjorth-Hansen, H., Janssen, J. J. W. M., Mustjoki, S., et al. (2024) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 71

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

Rousselot, P., Mollica, L., Guilhot, J., Guerci, A., Nicolini, F. E., Etienne, G., Legros, L., Charbonnier, A., Coiteux, V., Dartigeas, C., et al. (2021) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 46

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Ottmann, O., Saglio, G., Apperley, J. F., Arthur, C., Bullorsky, E., Charbonnier, A., Dipersio, J. F., Kantarjian, H., Khoury, H. J., Kim, D.-W., et al. (2018) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Dulucq, S., Nicolini, F. E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., et al. (2022) · Haematologica

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 17

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Balsat, M., Alcazer, V., Etienne, G., Huguet, F., Berger, M., Cayssials, E., Charbonnier, A., Escoffre-Barbe, M., Johnson-Ansah, H., Legros, L., et al. (2023) · Leukemia Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 5